[1] 王庆忠, 范云, 沈祁烨. 人类微生物组学与健康及其临床检验的需求[J]. 分子诊断与治疗杂志, 2018, 10(1):67-72. [2] NATALINI JG, SINGH S, SEGAL LN.The dynamic lung microbiome in health and disease[J]. Nat Rev Microbiol, 2023, 21(4):222-235. [3] HAN B, ZHENG R, ZENG H, et al.Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53. [4] GOTO T.Microbiota and lung cancer[J]. Semin Cancer Biol, 2022, 86(Pt 3):1-10. [5] KING A. Exploring the lung microbiome's role in disease[J]. Nature, 2024, Online ahead of print. [6] CHARLSON ES, BITTINGER K, HAAS AR, et al.Topographical continuity of bacterial populations in the healthy human respiratory tract[J]. Am J Respir Crit Care Med, 2011, 184(8):957-963. [7] HILTY M, BURKE C, PEDRO H, et al.Disordered microbial communities in asthmatic airways[J]. PloS one, 2010, 5(1):e8578. [8] DICKSON RP, ERB-DOWNWARD JR, MARTINEZ FJ, et al.The Microbiome and the Respiratory Tract[J]. Annu Rev Physiol, 2016, 78:481-504. [9] SHAH BK, SINGH B, WANG Y, et al.Mucus Hypersecretion in Chronic Obstructive Pulmonary Disease and Its Treatment[J]. Mediators Inflamm, 2023, 2023:8840594. [10] WYPYCH TP, WICKRAMASINGHE LC, MARSLAND BJ.The influence of the microbiome on respiratory health[J]. Nat Immunol, 2019, 20(10):1279-1290. [11] HUANG J, HUANG J.Microbial Biomarkers for Lung Cancer:Current Understandings and Limitations[J]. J Clin Med, 2022, 11(24):7298. [12] DICKSON RP, ERB-DOWNWARD JR, HUFFNAGLE GB.Towards an ecology of the lung:new conceptual models of pulmonary microbiology and pneumonia pathogenesis[J]. Lancet Respir Med, 2014, 2(3):238-246. [13] DICKSON RP, MARTINEZ FJ, HUFFNAGLE GB.The role of the microbiome in exacerbations of chronic lung diseases[J]. Lancet, 2014, 384(9944):691-702. [14] 陈丽霏, 张世倡, 肖林. 炎症性肠病中活性氧及抗氧化的研究进展[J]. 中国当代医药, 2020, 27(09):24-27. [15] TSAY JJ, WU BG, SULAIMAN I, et al.Lower Airway Dysbiosis Affects Lung Cancer Progression[J]. Cancer Discov, 2021, 11(2):293-307. [16] LU SSM, MOHAMMED Z, HäGGSTRöM C, et al. Antibiotics Use and Subsequent Risk of Colorectal Cancer:A Swedish Nationwide Population-Based Study[J]. J Natl Cancer Inst, 2022, 114(1):38-46. [17] DANG AT, MARSLAND BJ.Microbes, metabolites, and the gut-lung axis[J]. Mucosal Immunol, 2019, 12(4):843-850. [18] GEORGIOU K, MARINOV B, FAROOQI AA, et al.Gut Microbiota in Lung Cancer:Where Do We Stand?[J]. Int J Mol Sci, 2021, 22(19):10429. [19] GE Y, WANG X, GUO Y, et al.Gut microbiota influence tumor development and Alter interactions with the human immune system[J]. J Exp Clin Cancer Res, 2021, 40(1):42. [20] ASHIQUE S, DE RUBIS G, SIROHI E, et al.Short Chain Fatty Acids:Fundamental mediators of the gut-lung axis and their involvement in pulmonary diseases[J]. Chem Biol Interact, 2022, 368:110231. [21] STRICKER S, HAIN T, CHAO C M, et al.Respiratory and Intestinal Microbiota in Pediatric Lung Diseases-Current Evidence of the Gut-Lung Axis[J]. Int J Mol Sci, 2022, 23(12):6791. [22] NEJMAN D, LIVYATAN I, FUKS G, et al.The human tumor microbiome is composed of tumor type-specific intracellular bacteria[J]. Science, 2020, 368(6494):973-980. [23] HE Z, GHARAIBEH RZ, NEWSOME RC, et al.Campylobacter jejuni promotes colorectal tumorigenesis through the action of cytolethal distending toxin[J]. Gut, 2019, 68(2):289-300. [24] FELLOWS R, DENIZOT J, STELLATO C, et al.Microbiota derived short chain fatty acids promote histone crotonylation in the colon through histone deacetylases[J]. Nat Commun, 2018, 9(1):105. [25] LIU F, LI J, GUAN Y, et al.Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer[J]. Int J Biol Sci, 2019, 15(11):2381-2392. [26] GOODWIN AC, DESTEFANO SHIELDS CE, WU S, et al.Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis[J]. Proc Natl Acad Sci USA, 2011, 108(37):15354-15359. [27] GARRETT WS.Cancer and the microbiota[J]. Science, 2015, 348(6230):80-86. [28] 任清林, 何文博, 岳佳瑞. 两样本孟德尔随机化分析肠道菌群与肺癌的因果关系[J]. 中国胸心血管外科临床杂志, 2023, 30(11):1618-1627. [29] KEELY S, TALLEY NJ, HANSBRO PM.Pulmonary-intestinal cross-talk in mucosal inflammatory disease[J]. Mucosal Immunol, 2012, 5(1):7-18. [30] SANMAMED MF, CARRANZA-RUA O, ALFARO C, et al.Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins[J]. Clin Cancer Res, 2014, 20(22):5697-5707. [31] BIAGI E, NYLUND L, CANDELA M, et al.Through ageing, and beyond:gut microbiota and inflammatory status in seniors and centenarians[J]. PloS One, 2010, 5(5):e10667. [32] ANAND S, MANDE SS.Diet, Microbiota and Gut-Lung Connection[J]. Front Microbiol, 2018, 9:2147. [33] VIEIRA RS, CASTOLDI A, BASSO PJ, et al.Butyrate Attenuates Lung Inflammation by Negatively Modulating Th9 Cells[J]. Front Immunol, 2019, 10:67. [34] LI L, FANG Z, LIU X, et al.Lactobacillus reuteri attenuated allergic inflammation induced by HDM in the mouse and modulated gut microbes[J]. PloS One, 2020, 15(4):e0231865. [35] 葛怡俊, 曹超. 肺部微生态与肺癌的关系研究进展[J]. 新医学, 2023, 54(8):540-544. [36] GREATHOUSE KL, WHITE JR, VARGAS AJ, et al.Interaction between the microbiome and TP53 in human lung cancer[J]. Genome Biol, 2018, 19(1):123. [37] DE VISSER KE, JOYCE JA.The evolving tumor microenvironment:From cancer initiation to metastatic outgrowth[J]. Cancer Cell, 2023, 41(3):374-403. [38] LIU HX, TAO LL, ZHANG J, et al.Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects[J]. Int J Cancer, 2018, 142(4):769-778. [39] GALEANO NIÑO JL, WU H, LACOURSE KD, et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer[J]. Nature, 2022, 611(7937):810-817. [40] FU Y, LI J, CAI W, et al.The emerging tumor microbe microenvironment:From delineation to multidisciplinary approach-based interventions[J]. Acta Pharm Sin B, 2024, 14(4):1560-1591. [41] LI R, LI J, ZHOU X.Lung microbiome:new insights into the pathogenesis of respiratory diseases[J]. Signal Transduct Target Ther, 2024, 9(1):19. [42] LEE SH, SUNG JY, YONG D, et al.Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions[J]. Lung Cancer, 2016, 102:89-95. [43] LAROUMAGNE S, SALINAS-PINEDA A, HERMANT C, et al.Incidence and characteristics of bronchial colonisation in patient with lung cancer:a retrospective study of 388 cases[J]. Rev Mal Respir, 2011, 28(3):328-335. [44] XIA X, CHEN J, CHENG Y, et al.Comparative analysis of the lung microbiota in patients with respiratory infections, tuberculosis, and lung cancer:A preliminary study[J]. Front Cell Infect Microbiol, 2022, 12:1024867. [45] LIANG HY, LI XL, YU X S, et al.Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk:a systematic review[J]. Int J Cancer, 2009, 125(12):2936-2944. [46] LIU NN, YI C X, WEI LQ, et al.The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells[J]. Cancer Cell, 2024, 42(2):318-322. [47] NARUNSKY-HAZIZA L, SEPICH-POORE GD, LIVYATAN I, et al.Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions[J]. Cell, 2022, 185(20):3789-3806. [48] AKHTAR N, BANSAL JG.Risk factors of Lung Cancer in nonsmoker[J]. Curr Probl Cancer, 2017, 41(5):328-339. [49] ZHAI K, DING J, SHI HZ.HPV and lung cancer risk:a meta-analysis[J]. J Clin Virol, 2015, 63:84-90. [50] CARPAGNANO GE, KOUTELOU A, NATALICCHIO MI, et al.HPV in exhaled breath condensate of lung cancer patients[J]. Br J Cancer, 2011, 105(8):1183-1190. [51] CHENG YW, WU MF, WANG J, et al.Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation[J]. Cancer Res, 2007, 67(22):10686-10693. [52] CHEN FF, YAN JJ, LAI WW, et al.Epstein-Barr virus-associated nonsmall cell lung carcinoma:undifferentiated "lymphoepithelioma-like" carcinoma as a distinct entity with better prognosis[J]. Cancer, 1998, 82(12):2334-2342. [53] WANG S, XIONG H, YAN S, et al.Identification and Characterization of Epstein-Barr Virus Genomes in Lung Carcinoma Biopsy Samples by Next-Generation Sequencing Technology[J]. Sci Rep, 2016, 6:26156. [54] JAFARIAN AH, OMIDI-ASHRAFI A, MOHAMADIAN-ROSHAN N, et al.Association of Epstein Barr virus deoxyribonucleic acid with lung carcinoma[J]. Indian J Pathol Microbiol, 2013, 56(4):359-364. [55] BECNEL D, ABDELGHANI R, NANBO A, et al.Pathogenic Role of Epstein-Barr Virus in Lung Cancers[J]. Viruses, 2021, 13(5):877. [56] 王宁, 李刚, 龚胜. 非小细胞肺癌合并HIV感染/AIDS手术患者病理和临床特征及术后并发症影响因素分析[J]. 新发传染病电子杂志, 2024, 9(2):29-33. [57] BLAKE SJ, WOLF Y, BOURSI B, et al.Role of the microbiota in response to and recovery from cancer therapy[J]. Nat Rev Immunol, 2024, 24(5):308-325. [58] PINATO DJ, HOWLETT S, OTTAVIANI D, et al.Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer[J]. JAMA Oncol, 2019, 5(12):1774-1778. [59] JIN C, LAGOUDAS GK, ZHAO C, et al.Commensal Microbiota Promote Lung Cancer Development via γδ T Cells[J]. Cell, 2019, 176(5):998-1013. [60] KABWE M, DASHPER S, BACHRACH G, et al. Bacteriophage manipulation of the microbiome associated with tumour microenvironments-can this improve cancer therapeutic response?[J]. FEMS Microbiol Rev, 2021, 45(5):fuab017. [61] ZHANG M, ZHANG Y, SUN Y, et al.Intratumoral Microbiota Impacts the First-Line Treatment Efficacy and Survival in Non-Small Cell Lung Cancer Patients Free of Lung Infection[J]. J Healthc Eng, 2022, 2022:5466853. [62] HILMI M, NEUZILLET C, LEFèVRE JH, et al. Prognostic Value of Fusobacterium nucleatum after Abdominoperineal Resection for Anal Squamous Cell Carcinoma[J]. Cancers (Basel), 2022, 14(7):1606. |